Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993, Administered Via the Multi-dose Reservoir NEXThaler Dry Powder Inhaler and Via a HFA-pressurised Metered Dose Inhaler With and Without Valved Holding Chamber, in Healthy Volunteers

Trial Profile

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993, Administered Via the Multi-dose Reservoir NEXThaler Dry Powder Inhaler and Via a HFA-pressurised Metered Dose Inhaler With and Without Valved Holding Chamber, in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2016

At a glance

  • Drugs Beclometasone/formoterol/glycopyrrolate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics
  • Sponsors Chiesi Farmaceutici SpA
  • Most Recent Events

    • 22 Aug 2016 Status changed from recruiting to completed.
    • 20 Apr 2016 Status changed from not yet recruiting to recruiting.
    • 20 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top